U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C18H18N3O2S.Na.2H2O
Molecular Weight 399.44
Optical Activity ( + / - )
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NEPAPRAZOLE SODIUM DIHYDRATE

SMILES

O.O.[Na+].[H][C@]1(CCCCC2=C1N=CC=C2OC)[S@+]([O-])C3=NC4=C([N-]3)C=CC=C4

InChI

InChIKey=XVAZNFAGVOZGQO-RGJNJDGQSA-N
InChI=1S/C18H18N3O2S.Na.2H2O/c1-23-15-10-11-19-17-12(15)6-2-5-9-16(17)24(22)18-20-13-7-3-4-8-14(13)21-18;;;/h3-4,7-8,10-11,16H,2,5-6,9H2,1H3;;2*1H2/q-1;+1;;/t16-,24+;;;/m1.../s1

HIDE SMILES / InChI

Molecular Formula C18H19N3O2S
Molecular Weight 341.427
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Nepaprazole is a proton pump inhibitor of substituted 2-(2-pyridinylmethylsulfinyl)-1H-benzimidazole class evaluated as useful drug for the clinical treatment of peptic ulcer diseases. The effects of the TY-11345 (nepaprazole sodium salt) on gastric mucosal proton pump (H+/K(+)-ATPase) activity, gastric acid secretion and gastro-duodenal lesions were investigated in experimental animals. TY-11345 potently inhibited H+/K(+)-ATPase activity in isolated rabbit gastric mucosal microsomes and the inhibitory effect was enhanced under weak acid conditions. In Ghosh & Schild rats, intravenous injection of TY-11345 significantly inhibited gastric acid secretion stimulated by tetragastrin; the effect of TY-11345 was twice as potent as that of omeprazole. In pylorus ligated rats, TY-11345 inhibited basal gastric acid secretion by both the intraduodenal and oral routes with 9 and 5 times more greater potency than those of omeprazole, respectively. The antisecretory effect of TY-11345 persisted for more than 24 h in pylorus ligated rats. In experimental ulcer models, TY-11345 prevented the formation of water-immersion stress, ethanol or indomethacin-induced gastric lesions and mepirizole-induced duodenal lesions in rats. The antiulcer effects of TY-11345 were 3 to 15 times more potent than those of omeprazole. These results suggested that TY-11345 had potent antisecretory and antiulcer effects which are exerted by suppression of H+/K(+)-ATPase activity in gastric parietal cells. Nepaprazole sodium had been studied in phase II clinical trials for treatment of gastric ulser but this research has been discontinued.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P20648
Gene ID: 495.0
Gene Symbol: ATP4A
Target Organism: Homo sapiens (Human)
5.8 µM [IC50]
Target ID: P51164
Gene ID: 496.0
Gene Symbol: ATP4B
Target Organism: Homo sapiens (Human)
5.8 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Biochemical and pharmacological properties of a newly synthesized proton pump (H+/K(+)-ATPase) inhibitor, TY-11345 in experimental animals.
1993 Aug
Synthesis and antiulcer activities of novel 2-[(6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl)sulfinyl]-1H- benzimidazole analogues.
1994 Mar
Pharmacokinetic properties of a novel gastric proton pump inhibitor, (+/-)-2-[(4-methoxy-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9- yl)sulfinyl]-1H-benzimidazole sodium salt, in healthy subjects.
1994 Oct
Synthetic study of 2-[(6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9- yl)-sulfinyl]-1H-benzimidazole analogs and their biological properties as novel proton pump inhibitors.
1995 Mar
[Synthesis of stable solvates of monosodium 2-[R*s,9S*)-(4-methoxy-6,7,8, 9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl)sulfinyl]-1H-benzimidazole].
1996 Aug
Patents

Sample Use Guides

The pharmacokinetics and safety of TY-11345 [(+/-)-2-[(4-methoxy-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9- yl)sulfinyl]-1H-benzimidazole sodium salt; nepaprazole], a novel gastric proton pump inhibitor, were studied in healthy male volunteers after single (20, 40, and 80 mg) and repeated oral doses (60 mg, once daily for 7 days) as enteric-coated tablet.
Route of Administration: Oral
TY-11345 (nepaprazole) potently inhibited the H+/K+-ATPase activity of purified rabbit gastric mucosal microsomes in a concentration-dependent manner. The effects of TY-11345 were about 3 and 20 times more potent than that of omeprazole. The inhibitory effects of TY-11345 and omeprazole depended on the preincubation time. Nearly peak effects of TY-11345 and omeprazole were attained at 10 min and 30 min, respectively. However, for the 30 min preincubation, the inhibitory effects of TY-11345 and omeprazole at concentrations of 10 pM and 30 pM, respectively, were almost equal at these concentrations and the values were about 85%.
Substance Class Chemical
Created
by admin
on Sat Dec 16 18:02:25 GMT 2023
Edited
by admin
on Sat Dec 16 18:02:25 GMT 2023
Record UNII
OT6V161GY4
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NEPAPRAZOLE SODIUM DIHYDRATE
Common Name English
NEPAPRAZOLE SODIUM HYDRATE
Common Name English
PENAPRAZOLE SODIUM HYDRATE [JAN]
Common Name English
5H-CYCLOHEPTA(B)PYRIDINE, 9-(1H-BENZIMIDAZOL-2-YLSULFINYL)-6,7,8,9-TETRAHYDRO-4-METHOXY-, SODIUM SALT, DIHYDRATE, (R*,S*)-
Common Name English
(±)-5H-CYCLOHEPTA(B)PYRIDINE, 9-(1H-BENZIMIDAZOL-2-YLSULFINYL)-6,7,8,9-TETRAHYDRO-4-METHOXY-, SODIUM SALT, DIHYDRATE
Common Name English
PENAPRAZOLE SODIUM HYDRATE
JAN  
Common Name English
Code System Code Type Description
FDA UNII
OT6V161GY4
Created by admin on Sat Dec 16 18:02:25 GMT 2023 , Edited by admin on Sat Dec 16 18:02:25 GMT 2023
PRIMARY
PUBCHEM
71587594
Created by admin on Sat Dec 16 18:02:25 GMT 2023 , Edited by admin on Sat Dec 16 18:02:25 GMT 2023
PRIMARY
CAS
183380-24-7
Created by admin on Sat Dec 16 18:02:25 GMT 2023 , Edited by admin on Sat Dec 16 18:02:25 GMT 2023
PRIMARY
EPA CompTox
DTXSID10171417
Created by admin on Sat Dec 16 18:02:25 GMT 2023 , Edited by admin on Sat Dec 16 18:02:25 GMT 2023
PRIMARY
Related Record Type Details
ANHYDROUS->SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY